Free Trial

Tourmaline Bio Q1 2023 Earnings Report

$24.44 -1.22 (-4.75%)
(As of 12/3/2024 ET)

Tourmaline Bio Earnings Headlines

Tourmaline Bio price target raised to $49 from $48 at H.C. Wainwright
Expert: The most important message you’ll see in 2024
The message I'm sharing today could be the most important message of 2024. In short, America is being invaded… The invasion spreading across America is coming from the ports, highways, and railroads.
Tourmaline Bio files $350M mixed securities shelf
See More Tourmaline Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tourmaline Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tourmaline Bio and other key companies, straight to your email.

About Tourmaline Bio

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

View Tourmaline Bio Profile

More Earnings Resources from MarketBeat